Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $994,730.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 5,500 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the sale, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $0.34 on Thursday, hitting $175.74. 1,664,525 shares of the company were exchanged, compared to its average volume of 947,213. The company’s 50 day moving average price is $136.90 and its two-hundred day moving average price is $121.57. The firm has a market capitalization of $10.68 billion, a price-to-earnings ratio of -26.11, a PEG ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the company posted $6.54 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on JAZZ. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a research note on Monday. Wells Fargo & Company raised their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $195.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Picton Mahoney Asset Management increased its holdings in Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 269 shares in the last quarter. Farther Finance Advisors LLC raised its position in Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 234 shares during the last quarter. SVB Wealth LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $36,000. Finally, Hantz Financial Services Inc. increased its position in shares of Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.